Gilead Sciences (NASDAQ:GILD) will release its quarterly earnings report on Wednesday, 2024-11-06. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Gilead ...

In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against the other pharma stocks. Healthcare takes the concept of 'defensive' further than almost ...

Gilead Sciences (NASDAQ:GILD) is scheduled to announce Q3 earnings results on Wednesday, November 6th, after market close. Leerink sees the positive late-stage trial data on lenacapavir for HIV ...

Treatment with an experimental CAR-T therapy for multiple myeloma from Arcellx and Gilead Sciences resulted in zero cases of delayed neurotoxicity, including Parkinsonian symptoms and cranial ...

A cancer cell therapy developed by Arcellx and Gilead Sciences helped reduce or eliminate signs of multiple myeloma in 95% of people in advanced stages of disease, the companies said Monday.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against the other pharma ...

Following its massive success with hepatitis C drugs Sovaldi and Harvoni, everyone has been watching Gilead closely to see how it will try to sustain its stratospheric growth. It was already clear ...

Gilead Sciences' chief medical officer, Merdad Parsey, will leave the company in early 2025, becoming the latest in a series of high-profile departures involving senior R&D figures at top drugmakers.